StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Rating) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.
Several other research firms have also issued reports on EKSO. 500.com reaffirmed a “reiterates” rating on shares of Ekso Bionics in a research note on Friday, April 28th. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a research report on Thursday, March 30th.
Ekso Bionics Trading Up 0.3 %
NASDAQ EKSO opened at $1.48 on Wednesday. Ekso Bionics has a twelve month low of $1.03 and a twelve month high of $2.95. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.30 and a current ratio of 2.89. The stock has a market cap of $19.91 million, a price-to-earnings ratio of -1.31 and a beta of 1.80. The firm’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $1.49.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Essex Investment Management Co. LLC lifted its position in Ekso Bionics by 38.9% during the 4th quarter. Essex Investment Management Co. LLC now owns 444,057 shares of the company’s stock worth $528,000 after acquiring an additional 124,384 shares during the last quarter. Legato Capital Management LLC acquired a new position in Ekso Bionics during the 4th quarter worth $45,000. Strategic Wealth Investment Group LLC raised its position in shares of Ekso Bionics by 26.4% during the fourth quarter. Strategic Wealth Investment Group LLC now owns 28,336 shares of the company’s stock valued at $46,000 after buying an additional 5,917 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Ekso Bionics during the third quarter valued at about $28,000. Finally, Renaissance Technologies LLC raised its position in shares of Ekso Bionics by 153.4% during the second quarter. Renaissance Technologies LLC now owns 44,606 shares of the company’s stock valued at $74,000 after buying an additional 27,006 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets.
- Get a free copy of the StockNews.com research report on Ekso Bionics (EKSO)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.